SC Filed 2024-04-12 Event — SEC 0000947871-24-000373 →

ORBIMED ADVISORS LLC → Passage BIO, Inc. PASG

Stake: — Shares: —

Item 4 — Purpose of Transaction

Not extracted from this filing — typically because it's an amendment (13D/A) and Item 4 is unchanged from the parent filing. Read the raw SEC filing →

Cross-References

Insider Activity (last 365d)

7 transactions

3 buys · 2 sales · 2 awards/exercises

Issuer Cluster

5 13D/G filings on this issuer

4 other filings besides this one

Filer Track Record

142 filings by this filer

141 other filings in the data moat

Short Interest · settle 2026-08-31

DTC 5.19

101,638 shares short · -25.8% vs prior

Form 4 Insider Transactions · last 365d

Date	Insider	Role	Type	Shares	Price	Value
2026-03-16	Borthwick Kathleen	officer	Award	15,610	$7.64	$119K
2026-03-16	Chou William	director, officer	Award	58,000	$7.64	$443K
2026-01-08	Chou William	director, officer	Option exercise	10,000	—	—
2026-01-08	Borthwick Kathleen	officer	Option exercise	5,000	—	—
2026-01-08	Chou William	director, officer	Sale	4,076	$18.44	$75K
2026-01-08	Borthwick Kathleen	officer	Sale	2,062	$18.44	$38K
2025-09-15	Lynx1 Capital Management LP	10%+ owner	Buy	11,900	$6.99	$83K

Other 13D/G Filings on Passage BIO, Inc.

Filed	Form	Filer	Stake	Shares
2026-07-02	SCHEDULE 13D	Lynx1 Capital Management LP	21.00%	673,759	view →
2026-06-25	SCHEDULE 13G	Baselake Partners, LP	—	—	view →
2025-07-21	SCHEDULE	ORBIMED ADVISORS LLC	7.82%	243,878	view →
2021-01-27	SC	Frazier Life Sciences IX, L.P.	—	—	view →

Other Filings by ORBIMED ADVISORS LLC

Filed	Form	Issuer	Stake	Shares
2026-09-10	SCHEDULE 13D/A	Braveheart Bio, Inc.	13.50%	12,175,159	view →
2026-08-18	SCHEDULE 13D	BlossomHill Therapeutics, Inc.	8.90%	2,714,279	view →
2026-08-18	SCHEDULE 13D	Braveheart Bio, Inc.	17.20%	12,175,159	view →
2026-08-10	SCHEDULE 13D/A	MBX Biosciences, Inc.	—	3,074,853	view →
2026-08-05	SCHEDULE 13D	Yarrow Bioscience, Inc.	9.97%	266,306	view →
2026-07-29	SCHEDULE 13D	Scribe Therapeutics, Inc.	7.20%	1,348,825	view →
2026-07-20	SCHEDULE 13D/A	Q32 Bio Inc.	—	4,127,987	view →
2026-06-24	SCHEDULE 13D/A	Enliven Therapeutics, Inc. ELVN	—	6,774,507	view →
2026-06-17	SCHEDULE 13D/A	Enliven Therapeutics, Inc. ELVN	10.93%	7,634,630	view →
2026-06-15	SCHEDULE 13D/A	Shattuck Labs, Inc. STTK	—	9,021,127	view →
2026-06-01	SCHEDULE 13D/A	Q32 Bio Inc. QTTB	—	4,127,987	view →
2026-04-10	SCHEDULE 13D/A	Adicet Bio, Inc. ACET	8.80%	844,787	view →
2026-01-27	SCHEDULE	Corvus Pharmaceuticals, Inc. CRVS	10.30%	8,609,091	view →
2025-10-10	SCHEDULE	Adicet Bio, Inc. ACET	9.60%	14,772,598	view →
2025-09-30	SCHEDULE	MBX Biosciences, Inc. MBX	9.00%	4,002,887	view →
2025-07-21	SCHEDULE	Passage BIO, Inc. PASG	7.82%	243,878	view →
2025-05-14	SCHEDULE	Corvus Pharmaceuticals, Inc. CRVS	12.20%	9,785,423	view →
2025-04-11	SCHEDULE	Compass Therapeutics, Inc. CMPX	11.00%	15,219,994	view →
2025-01-29	SCHEDULE	Traws Pharma, Inc. TRAW	19.90%	760,824	view →
2024-11-12	SC	Third Harmonic Bio, Inc.	—	—	view →

Showing 20 of 141

Want this depth on every filing the moment it hits SEC EDGAR?

Full feed access · API · daily intelligence brief · custom alerts. From $49/mo.

See pricing →